Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Trading in otc pink is nothing wrong with it. The company eliminated all the toxic financing and has raised enough money to uplift.
The company could acquire cyto after the merger gets completed.
Thanks!
SPTAU CYTO both of these companies have the same CEO Michael Handley and strong backing of investment banking Kingswood Capital & Bridgeway Capital Partners
Very bullish for CBLI snd IMUN shareholders!
Biotech-focused SPAC Sparta Healthcare Acquisition files for a $100 million IPO
Sparta Healthcare Acquisition is led by CEO and Chairman Michael Handley, who has served as the CEO of Cytocom since 2020 and has assisted in or led the global commercialization of 17 devices or drugs over the course of his career, and CFO Nicholas Hemmerly, the current Head of Investment Banking at Bridgeway Capital Partners. The company plans to leverage management's experience and target the North American biotech and therapeutic sectors, focusing on businesses with mid-to-late stage therapeutic candidates across a variety of indications.
No dilution Outstanding Shares
483,714 as of 07/06/2021, almost 2 months since RS the company hasn’t diluted the shareholders
Regardless of dilution the company still worth at least 200-500M. Keep spreading panic
the merger has been approved by the shareholders
https://www.streetinsider.com/dr/news.php?id=18647881
Interesting blurb Combined companies “developing therapies and plans to launch therapies into the $48.7 billion gastrointestinal market, the $84.3 billion therapeutic oncology market, the $82.5 billion hematology market and the $125.0 billion autoimmune market.”
Acquisition or reverse merger but IMO reverse merger is more likely
Penny stock Advaxis and Biosight Announce Entry into Reverse Merger Agreement
IMUN is perfect to do reverse merger with another private company
CBLI nice run today and 1 week from completion of the merger
No dilution has occurred
483,714 OS as of 06/23/2021
2.7M MCAP
Current CYTO equity stake $12M-15M
Cyto will issue IMUN 2.3-3M shares after the merger. The value of the shares are worth $12M-$15.7M currently and market cap is $2.7M
$CBLI keep going up and combined companies plenty of cash $30M
CBLI nice run today. Stockholders’ Meeting
to Be Held on July 6, 2021 at 10:00 a.m. Eastern Time via the internet. The merger should be closed 2 week of July or earlier. Huge catalyst for IMUN
The company was upgraded by OTC
Penny stock exempt under SEC is as follow:
under SEC under Rule 240.3a51-1 because it meets one of the following tests: 1) A price of over $5 per share, 2) the issuer has Average Revenue of at least $6 million for the last 3 years, or 3) the issuer has Net Tangible Assets in excess of $2 million if ...
Take look what happened to ORPH 880% jump in one 1 day and cyto could be the next one
News out Cleveland Biolabs (CBLI) Patent App #20210169972 Published Today for "USE OF TOLL-LIKE RECEPTOR AGONIST FOR TREATING CANCER"
News out Cleveland Biolabs (CBLI) Patent App #20210169972 Published Today for "USE OF TOLL-LIKE RECEPTOR AGONIST FOR TREATING CANCER"
My focus is on IMUN
IMUN stock price is irrelevant because all wvaluation is on cyto/CBLI.
IMUN $2.5M Market cap and CBLI current equity stake is roughly $13-$20M.
Ask yourself why would any investor invested $700,000 and a maximum of $1,500,000 without stock conversion which is extremely risky unless they know something that is not public yet. non convertible debt which is unheard of for otc stock
I guess you didn’t read the PR
According to the agreement, the investors will lend a minimum of $700,000 and a maximum of $1,500,000 to the Company in exchange for non-convertible promissory notes bearing interest at 5%.
What different does make but she also converted the convertible debt into shares. All the debt holders could have exercised much lower price than $5 with 60% discounted from the 10 days average price.
Let’s not forget Noreen is the largest share holder and she has increased significantly equity stake in company. Why would she increased the equity stake?
Form 3 273.K shares + 13D 57K = 331K post split or 331M pre split shares total
Form 3 filed
ROGOFF FAMILY TRUST DTD 20K shares
Yanowitz Joel 20K +4570 shares already owned
Sasko George 10K+ 30,155 shares owned already
Rhodes Deane 5K shares
RASTER INVESTMENTS, Inc 20K+5650 shares already owned
Puskadi Paul 5K + 11.5K shares already owned
Global Reverb Corp 49.77k shares
Dunk Chris 35K + 2,146 K shares already owned
DAILEY ROBERT JACKMAN 2,629 +12K already owned
Curley James Norman 2.170K shares
CUNNINGHAM Alan 20K shares +1.225K already owned
BOZARTH Roger Dale 10K + 7.1K shares already owned
13D filed Griffin Noreen 57K
Many institutional investors/ large investors are buying shares at market price which is unheard for penny stock.
Basically convertible debt is eliminated and converted into shares. Which is very good sign
All the valuation is on CBLI and IMUN is very attractive for acquisition/merger
Nice!
Why a note holders AKA loan sharks agreed to converted into shares without knowing something is happening?
Great news
Orlando, Florida , June 04, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTC-PINK: IMUN) (the "Company") announced today that the Company has received and signed a non-binding term sheet to enter into an agreement that would provide working capital and wipe out a significant portion of its long-standing Debt.
$700,000 and a maximum of $1,500,000 to the Company in exchange for non-convertible promissory notes bearing interest at 5%.
CBLI filed S4/A On April 26, 2021, Cytocom entered into a Loan and Security Agreement (“LSA”) for a $15 million loan with Avenue Venture Opportunities Fund, L.P. (“Avenue”). Under the terms of the LSA, Cytocom borrowed $15 million at closing.
Combined companies have roughly 30M in cash
Over the next 12 months, Cytocom believes it will require between $25 million and $40 million to meet its ongoing and projected expenses and obligations.
WOW Griffin Noreen filed form 4 60K shares at exercise price $5
https://www.streetinsider.com/dr/news.php?id=18524856
Thanks! I have been saying this for long time that the market cap is tremendously low.
I can’t open
Clearly the company is tremendously undervalued. More great News to come
ERHC has absolutely nothing in comment with imund. Secondly imund 3M market cap is ridiculous low specially cyto equity stake is worth currently 13-18M and could be worth a lot more after the merger.